Effect of doxycycline in nasal polyps

Effect of doxycycline in chronic rhinosinusitis with nasal polyps

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210403050817N1

Enrollment

Registered

2021-05-29

Start date

2021-05-31

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinosinusitis with Nasal Polyps. Nasal polyp

Interventions

Intervention 1: Intervention group: Nasal Fluticasone Spray 100 micrograms twice daily, oral Montelukast 10 mg daily, Nasal irrigation, oral Doxycycline (manufactured by Behshad Darou, Iran) 200 mg

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with chronic rhinosinusitis with nasal polyps Age between 18 to 60 years Moderate to severe disease

Exclusion criteria

Exclusion criteria: Pregnancy Breast feeding Allergy to doxycycline History of sinus surgery within the last 3 months Antibiotic consumption within the last month Liver failure Renal failure Warfarin consumption

Design outcomes

Primary

Measure	Time frame
Quality of life based on Sino-Nasal Outcome Test 22 (SNOT-22) questionnaire. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later) and 4 weeks after treatment completion. Method of measurement: Sino-Nasal Outcome Test 22 (SNOT-22) questionnaire.	—

Secondary

Measure	Time frame
Nasal congestion score based on visual analogue scale. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later) and 4 weeks after treatment completion. Method of measurement: Visual Analogue Scale.;Score of decreased sense of smell based on visual analogue scale. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later) and 4 weeks after treatment completion. Method of measurement: Visual Analogue Scale.;Anterior nasal discharge score based on visual analogue scale. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later) and 4 weeks after treatment completion. Method of measurement: Visual Analogue Scale.;Posterior nasal discharge score based on visual analogue scale. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later) and 4 weeks after treatment completion. Method of measurement: Visual Analogue Scale.;Peak nasal inspiratory flow (PNIF). Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later). Method of measurement: Peak nasal inspiratory flow meter.;Nasal polyp size. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later). Method of measurement: Lund-MacKay score on low-dose CT scan.	—

Measure

Time frame

Nasal congestion score based on visual analogue scale. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later) and 4 weeks after treatment completion. Method of measurement: Visual Analogue Scale.;Score of decreased sense of smell based on visual analogue scale. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later) and 4 weeks after treatment completion. Method of measurement: Visual Analogue Scale.;Anterior nasal discharge score based on visual analogue scale. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later) and 4 weeks after treatment completion. Method of measurement: Visual Analogue Scale.;Posterior nasal discharge score based on visual analogue scale. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later) and 4 weeks after treatment completion. Method of measurement: Visual Analogue Scale.;Peak nasal inspiratory flow (PNIF). Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later). Method of measurement: Peak nasal inspiratory flow meter.;Nasal polyp size. Timepoint: Beginning of the intervention, At the end of the intervention (6 weeks later). Method of measurement: Lund-MacKay score on low-dose CT scan.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Atashrazm

Iran University of Medical Sciences

dr.atashrazm@gmail.com+98 21 6655 4933

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026